Humanitas Clinical and Research Center - IRCCS -, via Manzoni 56, 20089 Rozzano (Mi), Italy.
IBD Unit Universidade Federal de Sao Paulo, Sao Paulo, Brazil.
Curr Drug Targets. 2021;22(7):760-769. doi: 10.2174/1389450122999210120205607.
Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are chronic inflammatory diseases of the gastrointestinal tract. In the last few years, the development of biological agents targeting cytokines and receptors involved in IBD pathogenesis has led to better outcomes and has improved the course of the disease. Despite their effectiveness, drugs such as tumor necrosis factor (TNF) inhibitors, anti-Interleukin-12/23 and anti-integrins, do not induce a response in about one-third of patients, and 40% of patients lose response over time. Therefore, more efficient therapies are required. Recent studies showed that TL1A (Tumor necrosis factor-like cytokine 1A) acts as a regulator of mucosal immunity and participates in immunological pathways involved in the IBD pathogenesis. In this review article, we analyze the role of TL1A as a new potential target therapy in IBD patients.
炎症性肠病（IBD），包括溃疡性结肠炎（UC）和克罗恩病（CD），是胃肠道的慢性炎症性疾病。在过去的几年中，针对细胞因子和受体的生物制剂的发展靶向 IBD 发病机制导致了更好的结果，并改善了疾病进程。尽管它们有效，但诸如肿瘤坏死因子（TNF）抑制剂、抗白细胞介素-12/23 和抗整合素等药物并未在约三分之一的患者中引起反应，并且 40%的患者随着时间的推移失去反应。因此，需要更有效的治疗方法。最近的研究表明，TL1A（肿瘤坏死因子样细胞因子 1A）作为黏膜免疫的调节剂发挥作用，并参与 IBD 发病机制中涉及的免疫途径。在这篇综述文章中，我们分析了 TL1A 作为 IBD 患者新的潜在靶向治疗的作用。
